{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:32:38Z","timestamp":1792553558175,"version":"4.5.0"},"reference-count":327,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41585-025-01092-w","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:46:39Z","timestamp":1760370399000},"page":"236-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The hypoxic ECM and neutrophils in MIBC immunotherapy resistance"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1928-8150","authenticated-orcid":false,"given":"Fraser","family":"Child","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5791-9140","authenticated-orcid":false,"given":"Sapna","family":"Lunj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Vanesa","family":"Biolatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado Guerrero","family":"Quiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1092_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 244\u2013258 (2022).","journal-title":"Ann. Oncol."},{"key":"1092_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes, J. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331 (2024).","journal-title":"Eur. Urol."},{"key":"1092_CR3","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.eururo.2011.03.023","volume":"59","author":"A Stenzl","year":"2011","unstructured":"Stenzl, A. et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur. Urol. 59, 1009\u20131018 (2011).","journal-title":"Eur. Urol."},{"key":"1092_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","volume":"22","author":"A Choudhury","year":"2021","unstructured":"Choudhury, A. et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 22, 246\u2013255 (2021).","journal-title":"Lancet Oncol."},{"key":"1092_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1200\/JCO.2010.31.5721","volume":"29","author":"A Choudhury","year":"2011","unstructured":"Choudhury, A. et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J. Clin. Oncol. 29, 733\u2013738 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1092_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"1092_CR7","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA: A Cancer J. Clin. 70, 404\u2013423 (2020).","journal-title":"CA: A Cancer J. Clin."},{"key":"1092_CR8","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Von Der Maase","year":"2005","unstructured":"Von Der Maase, H. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602\u20134608 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1092_CR9","doi-asserted-by":"publisher","first-page":"175628722211477","DOI":"10.1177\/17562872221147760","volume":"15","author":"E-m Yu","year":"2023","unstructured":"Yu, E. -m, Mudireddy, M., Biswas, R. & Aragon-Ching, J. B. The role of switch maintenance therapy in urothelial cancers. Ther. Adv. Urol. 15, 17562872221147760 (2023).","journal-title":"Ther. Adv. Urol."},{"key":"1092_CR10","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","volume":"30","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt, J. et al. Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J. Clin. Oncol. 30, 1107\u20131113 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1092_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.21037\/tau.2016.08.23","volume":"5","author":"M Abufaraj","year":"2016","unstructured":"Abufaraj, M. et al. Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Transl. Androl. Urol. 5, 735\u2013744 (2016).","journal-title":"Transl. Androl. Urol."},{"key":"1092_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","volume":"13","author":"A Lopez-Beltran","year":"2021","unstructured":"Lopez-Beltran, A. et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers 13, 131 (2021).","journal-title":"Cancers"},{"key":"1092_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1092_CR14","doi-asserted-by":"publisher","first-page":"20468","DOI":"10.18632\/aging.203429","volume":"13","author":"F Li","year":"2021","unstructured":"Li, F. et al. The efficacy and safety of PD-1\/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials. Aging 13, 20468\u201320480 (2021).","journal-title":"Aging"},{"key":"1092_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201102147","volume":"196","author":"P Lu","year":"2012","unstructured":"Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196, 395\u2013406 (2012).","journal-title":"J. Cell Biol."},{"key":"1092_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.15252\/embr.201439246","volume":"15","author":"MW Pickup","year":"2014","unstructured":"Pickup, M. W., Mouw, J. K. & Weaver, V. M. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 15, 1243\u20131253 (2014).","journal-title":"EMBO Rep."},{"key":"1092_CR17","unstructured":"Mircea Ivan, X. H. Tumor Microenvironment and Cellular Stress. 1, (Springer,2014). 290."},{"key":"1092_CR18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/blood.V82.3.704.704","volume":"82","author":"I Beck","year":"1993","unstructured":"Beck, I., Weinmann, R. & Caro, J. Characterization of hypoxia-responsive enhancer in the human erythropoietin gene shows presence of hypoxia-inducible 120-Kd nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells. Blood 82, 704\u2013711 (1993).","journal-title":"Blood"},{"key":"1092_CR19","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1182\/blood.V82.12.3610.3610","volume":"82","author":"GL Wang","year":"1993","unstructured":"Wang, G. L. & Semenza, G. L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82, 3610\u20133615 (1993).","journal-title":"Blood"},{"key":"1092_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0889-8588(18)30134-5","volume":"8","author":"GL Semenza","year":"1994","unstructured":"Semenza, G. L. Regulation of erythropoietin production: new insights into molecular mechanisms of oxygen homeostasis. Hematol. Oncol. Clin. North. Am. 8, 863\u2013884 (1994).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"1092_CR21","doi-asserted-by":"publisher","first-page":"23757","DOI":"10.1016\/S0021-9258(17)31580-6","volume":"269","author":"GL Semenza","year":"1994","unstructured":"Semenza, G. L., Roth, P. H., Fang, H.-M. & Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269, 23757\u201323763 (1994).","journal-title":"J. Biol. Chem."},{"key":"1092_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccr.2006.08.026","volume":"10","author":"L Holmquist-Mengelbier","year":"2006","unstructured":"Holmquist-Mengelbier, L. et al. Recruitment of HIF-1\u03b1 and HIF-2\u03b1 to common target genes is differentially regulated in neuroblastoma: HIF-2\u03b1 promotes an aggressive phenotype. Cancer Cell 10, 413\u2013423 (2006).","journal-title":"Cancer Cell"},{"key":"1092_CR23","doi-asserted-by":"publisher","first-page":"32405","DOI":"10.1074\/jbc.C200328200","volume":"277","author":"Y Makino","year":"2002","unstructured":"Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H. & Poellinger, L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3\u03b1 locus. J. Biol. Chem. 277, 32405\u201332408 (2002).","journal-title":"J. Biol. Chem."},{"key":"1092_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399\u2013408 (2012).","journal-title":"Cell"},{"key":"1092_CR25","doi-asserted-by":"publisher","first-page":"63138","DOI":"10.18632\/oncotarget.11257","volume":"7","author":"A Peixoto","year":"2016","unstructured":"Peixoto, A. et al. Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension. Oncotarget 7, 63138\u201363157 (2016).","journal-title":"Oncotarget"},{"key":"1092_CR26","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.bjc.6601260","volume":"89","author":"PJ Hoskin","year":"2003","unstructured":"Hoskin, P. J., Sibtain, A., Daley, F. M. & Wilson, G. D. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br. J. Cancer 89, 1290\u20131297 (2003).","journal-title":"Br. J. Cancer"},{"key":"1092_CR27","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1016\/j.clon.2021.08.014","volume":"33","author":"MR Horsman","year":"2021","unstructured":"Horsman, M. R., S\u00f8rensen, B. S., Busk, M. & Siemann, D. W. Therapeutic modification of hypoxia. Clin. Oncol. 33, e492\u2013e509 (2021).","journal-title":"Clin. Oncol."},{"key":"1092_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nrc3726","volume":"14","author":"DM Gilkes","year":"2014","unstructured":"Gilkes, D. M., Semenza, G. L. & Wirtz, D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 14, 430\u2013439 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"1092_CR29","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).","journal-title":"Nat. Commun."},{"key":"1092_CR30","doi-asserted-by":"publisher","unstructured":"Guerrero Quiles, C. et al. Hypoxia-induced extracellular matrix changes are conserved in cancer and directly impact radiotherapy benefit. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.04.04.647191 (2025).","DOI":"10.1101\/2025.04.04.647191"},{"key":"1092_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1331355","volume":"14","author":"KJ Bigos","year":"2024","unstructured":"Bigos, K. J. et al. Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours. Front. Oncol. 14, 1331355\u00a0(2024).","journal-title":"Front. Oncol."},{"key":"1092_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.semcancer.2023.11.008","volume":"97","author":"R Abou Khouzam","year":"2023","unstructured":"Abou Khouzam, R. et al. Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: impact on cancer immunotherapy. Semin. Cancer Biol. 97, 104\u2013123 (2023).","journal-title":"Semin. Cancer Biol."},{"key":"1092_CR33","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3390\/cells9040992","volume":"9","author":"A Vito","year":"2020","unstructured":"Vito, A., El-Saves, N. & Mossman, K. Hypoxia-driven immune escape in the tumor microenvironment. Cells 9, 992\u00a0(2020).","journal-title":"Cells"},{"key":"1092_CR34","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.3390\/ijms24108956","volume":"24","author":"V Smith","year":"2023","unstructured":"Smith, V. et al. Hypoxia is associated with increased immune infiltrates and both anti-tumour and immune suppressive signalling in muscle-invasive bladder cancer. Int. J. Mol. Sci. 24, 8956 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1092_CR35","doi-asserted-by":"publisher","first-page":"1802176","DOI":"10.1080\/2162402X.2020.1802176","volume":"9","author":"Z Xiang","year":"2020","unstructured":"Xiang, Z. et al. Intratumoral CCR5+ neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses. Oncoimmunology 9, 1802176 (2020).","journal-title":"Oncoimmunology"},{"key":"1092_CR36","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash, J. & Shaked, Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 14, 1375\u20131388 (2024).","journal-title":"Cancer Discov."},{"key":"1092_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/biology12020218","volume":"12","author":"S Dutta","year":"2023","unstructured":"Dutta, S., Ganguly, A., Chatterjee, K., Spada, S. & Mukherjee, S. Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors. Biology 12, 218 (2023).","journal-title":"Biology"},{"key":"1092_CR38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1634\/theoncologist.2015-0282","volume":"21","author":"JL Messerschmidt","year":"2016","unstructured":"Messerschmidt, J. L., Prendergast, G. C. & Messerschmidt, G. L. How cancers escape immune destruction and mechanisms of action for the new significantly active immune therapies: helping nonimmunologists decipher recent advances. Oncologist 21, 233\u2013243 (2016).","journal-title":"Oncologist"},{"key":"1092_CR39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab, H. O. et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combination, and clinical outcome. Front. Pharmacol. 8, 561\u00a0(2017).","journal-title":"Front. Pharmacol."},{"key":"1092_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","volume":"11","author":"X Li","year":"2018","unstructured":"Li, X., Shao, C., Shi, Y. & Han, W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J. Hematol. Oncol. 11, 31 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"1092_CR41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0022-5347(18)31107-8","volume":"177","author":"BA Inman","year":"2007","unstructured":"Inman, B. A. et al. 879: PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. J. Urol. 177, 292\u2013292 (2007).","journal-title":"J. Urol."},{"key":"1092_CR42","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.3892\/or.2015.3933","volume":"33","author":"Y Huang","year":"2015","unstructured":"Huang, Y. et al. The prognostic significance of PD-L1 in bladder cancer. Oncol. Rep. 33, 3075\u20133084 (2015).","journal-title":"Oncol. Rep."},{"key":"1092_CR43","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/cas.13887","volume":"110","author":"B Wang","year":"2019","unstructured":"Wang, B. et al. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci. 110, 489\u2013498 (2019).","journal-title":"Cancer Sci."},{"key":"1092_CR44","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/cancers12051181","volume":"12","author":"M Wo\u0142\u0105cewicz","year":"2020","unstructured":"Wo\u0142\u0105cewicz, M. et al. Immunotherapy in bladder cancer: current methods and future perspectives. Cancers 12, 1181 (2020).","journal-title":"Cancers"},{"key":"1092_CR45","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773\u20131786 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1092_CR46","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04223856 (2025)."},{"key":"1092_CR47","doi-asserted-by":"publisher","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","volume":"34","author":"TB Powles","year":"2023","unstructured":"Powles, T. B. et al. LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC). Ann. Oncol. 34, S1340 (2023).","journal-title":"Ann. Oncol."},{"key":"1092_CR48","unstructured":"FDA. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer (2023)."},{"key":"1092_CR49","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid, P. M. et al. Enfortumab vedotin antibody\u2013drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 76, 3003\u20133013 (2016).","journal-title":"Cancer Res."},{"key":"1092_CR50","doi-asserted-by":"publisher","first-page":"19543","DOI":"10.1074\/jbc.M410943200","volume":"280","author":"S Fabre-Lafay","year":"2005","unstructured":"Fabre-Lafay, S. et al. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-\u03b1-converting enzyme (TACE)\/ADAM-17. J. Biol. Chem. 280, 19543\u201319550 (2005).","journal-title":"J. Biol. Chem."},{"key":"1092_CR51","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/eji.200535257","volume":"36","author":"B Walcheck","year":"2006","unstructured":"Walcheck, B. et al. ADAM17 activity during human neutrophil activation and apoptosis. Eur. J. Immunol. 36, 968\u2013976 (2006).","journal-title":"Eur. J. Immunol."},{"key":"1092_CR52","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1182\/blood-2008-04-152330","volume":"113","author":"RR Koenen","year":"2009","unstructured":"Koenen, R. R. et al. Regulated release and functional modulation of junctional adhesion molecule a by disintegrin metalloproteinases. Blood 113, 4799\u20134809 (2009).","journal-title":"Blood"},{"key":"1092_CR53","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1161\/CIRCRESAHA.109.207415","volume":"106","author":"G Weskamp","year":"2010","unstructured":"Weskamp, G. et al. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ. Res. 106, 932\u2013940 (2010).","journal-title":"Circ. Res."},{"key":"1092_CR54","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/jcm10040764","volume":"10","author":"R Pichler","year":"2021","unstructured":"Pichler, R. et al. Expression of ADAM proteases in bladder cancer patients with BCG failure: a pilot study. J. Clin. Med. 10, 764 (2021).","journal-title":"J. Clin. Med."},{"key":"1092_CR55","doi-asserted-by":"publisher","first-page":"103838","DOI":"10.1016\/j.breast.2024.103838","volume":"79","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Targeted therapeutic strategies for nectin-4 in breast cancer: recent advances and future prospects. Breast 79, 103838 (2025).","journal-title":"Breast"},{"key":"1092_CR56","doi-asserted-by":"publisher","first-page":"109902","DOI":"10.1016\/j.cellsig.2020.109902","volume":"80","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee, S., Sinha, S., Molla, S., Hembram, K. C. & Kundu, C. N. PARP inhibitor veliparib (ABT-888) enhances the anti-angiogenic potentiality of curcumin through deregulation of NECTIN-4 in oral cancer: role of nitric oxide (NO). Cell Signal. 80, 109902 (2021).","journal-title":"Cell Signal."},{"key":"1092_CR57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2016.02.049","volume":"375","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. A novel PI3K\/AKT signaling axis mediates nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett. 375, 179\u2013189 (2016).","journal-title":"Cancer Lett."},{"key":"1092_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000266","volume":"8","author":"A Reches","year":"2020","unstructured":"Reches, A. et al. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. J. Immunother. Cancer 8, e000266 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1092_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"J-M Chauvin","year":"2020","unstructured":"Chauvin, J.-M. & Zarour, H. M. TIGIT in cancer immunotherapy. J. Immunother. Cancer 8, e000957 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1092_CR60","doi-asserted-by":"publisher","first-page":"1744980","DOI":"10.1080\/2162402X.2020.1744980","volume":"9","author":"JJ Orme","year":"2020","unstructured":"Orme, J. J. et al. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology 9, 1744980 (2020).","journal-title":"Oncoimmunology"},{"key":"1092_CR61","doi-asserted-by":"publisher","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","volume":"129","author":"J Han","year":"2020","unstructured":"Han, J., Gu, X., Li, Y. & Wu, Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed. Pharmacother. 129, 110393 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"1092_CR62","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","volume":"27","author":"CE Chu","year":"2021","unstructured":"Chu, C. E. et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin. Cancer Res. 27, 5123\u20135130 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1092_CR63","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/sj.bjc.6605450","volume":"102","author":"FM Buffa","year":"2010","unstructured":"Buffa, F. M., Harris, A. L., West, C. M. & Miller, C. J. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br. J. Cancer 102, 428\u2013435 (2010).","journal-title":"Br. J. Cancer"},{"key":"1092_CR64","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-17-0038","volume":"23","author":"L Yang","year":"2017","unstructured":"Yang, L. et al. A gene signature for selecting benefit from hypoxia modification of radiotherapy for high-risk bladder cancer patients. Clin. Cancer Res. 23, 4761\u20134768 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1092_CR65","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.biocel.2018.07.011","volume":"102","author":"S Siddharth","year":"2018","unstructured":"Siddharth, S. et al. The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-\u03b24. Int. J. Biochem. Cell Biol. 102, 151\u2013160 (2018).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1092_CR66","doi-asserted-by":"publisher","first-page":"a004903","DOI":"10.1101\/cshperspect.a004903","volume":"4","author":"RO Hynes","year":"2012","unstructured":"Hynes, R. O. & Naba, A. Overview of the matrisome\u2014an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 4, a004903 (2012).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1092_CR67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.matbio.2015.06.003","volume":"49","author":"A Naba","year":"2016","unstructured":"Naba, A. et al. The extracellular matrix: tools and insights for the \u201comics\u201d era. Matrix Biol. 49, 10\u201324 (2016).","journal-title":"Matrix Biol."},{"key":"1092_CR68","doi-asserted-by":"publisher","first-page":"M111 014647","DOI":"10.1074\/mcp.M111.014647","volume":"11","author":"A Naba","year":"2012","unstructured":"Naba, A. et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell Proteomics 11, M111 014647 (2012).","journal-title":"Mol. Cell Proteomics"},{"key":"1092_CR69","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1126\/science.1176009","volume":"326","author":"RO Hynes","year":"2009","unstructured":"Hynes, R. O. The extracellular matrix: not just pretty fibrils. Science 326, 1216\u20131219 (2009).","journal-title":"Science"},{"key":"1092_CR70","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1242\/jcs.023820","volume":"123","author":"C Frantz","year":"2010","unstructured":"Frantz, C., Stewart, K. M. & Weaver, V. M. The extracellular matrix at a glance. J. Cell Sci. 123, 4195\u20134200 (2010).","journal-title":"J. Cell Sci."},{"key":"1092_CR71","doi-asserted-by":"publisher","first-page":"a005066","DOI":"10.1101\/cshperspect.a005066","volume":"2","author":"MA Schwartz","year":"2010","unstructured":"Schwartz, M. A. Integrins and extracellular matrix in mechanotransduction. Cold Spring Harb. Perspect. Biol. 2, a005066 (2010).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1092_CR72","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.devcel.2013.02.012","volume":"24","author":"H Wolfenson","year":"2013","unstructured":"Wolfenson, H., Lavelin, I. & Geiger, B. Dynamic regulation of the structure and functions of integrin adhesions. Dev. Cell 24, 447\u2013458 (2013).","journal-title":"Dev. Cell"},{"key":"1092_CR73","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673\u2013687 (2002).","journal-title":"Cell"},{"key":"1092_CR74","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s004410100417","volume":"305","author":"A van der Flier","year":"2001","unstructured":"van der Flier, A. & Sonnenberg, A. Function and interactions of integrins. Cell Tissue Res. 305, 285\u2013298 (2001).","journal-title":"Cell Tissue Res."},{"key":"1092_CR75","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.1038\/ncb0402-e65","volume":"4","author":"MA Schwartz","year":"2002","unstructured":"Schwartz, M. A. & Ginsberg, M. H. Networks and crosstalk: integrin signalling spreads. Nat. Cell Biol. 4, E65\u2013E68 (2002).","journal-title":"Nat. Cell Biol."},{"key":"1092_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7265","volume":"6","author":"J Robertson","year":"2015","unstructured":"Robertson, J. et al. Defining the phospho-adhesome through the phosphoproteomic analysis of integrin signalling. Nat. Commun. 6, 6265 (2015).","journal-title":"Nat. Commun."},{"key":"1092_CR77","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/path.1400","volume":"200","author":"I Stamenkovic","year":"2003","unstructured":"Stamenkovic, I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J. Pathol. 200, 448\u2013464 (2003).","journal-title":"J. Pathol."},{"key":"1092_CR78","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ceb.2004.07.010","volume":"16","author":"JD Mott","year":"2004","unstructured":"Mott, J. D. & Werb, Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16, 558\u2013564 (2004).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1092_CR79","first-page":"547","volume":"68","author":"S Watroba","year":"2021","unstructured":"Watroba, S., Wisniowski, T., Bryda, J. & Kurzepa, J. The role of matrix metalloproteinases in pathogenesis of human bladder cancer. Acta Biochim. Pol. 68, 547\u2013555 (2021).","journal-title":"Acta Biochim. Pol."},{"key":"1092_CR80","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans, C., Chou, J. & Werb, Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15, 786\u2013801 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1092_CR81","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/19336934.2022.2076539","volume":"16","author":"Y Matsubayashi","year":"2022","unstructured":"Matsubayashi, Y. Dynamic movement and turnover of extracellular matrices during tissue development and maintenance. Fly 16, 248\u2013274 (2022).","journal-title":"Fly"},{"key":"1092_CR82","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/biom14091186","volume":"14","author":"A Berdiaki","year":"2024","unstructured":"Berdiaki, A. et al. Extracellular matrix components and mechanosensing pathways in health and disease. Biomolecules 14, 1186 (2024).","journal-title":"Biomolecules"},{"key":"1092_CR83","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.3390\/ijms21249739","volume":"21","author":"GA Cabral-Pacheco","year":"2020","unstructured":"Cabral-Pacheco, G. A. et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int. J. Mol. 21, 9739\u00a0(2020).","journal-title":"Int. J. Mol."},{"key":"1092_CR84","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.tibtech.2015.01.004","volume":"33","author":"R Malik","year":"2015","unstructured":"Malik, R., Lelkes, P. I. & Cukierman, E. Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. Trends Biotechnol. 33, 230\u2013236 (2015).","journal-title":"Trends Biotechnol."},{"key":"1092_CR85","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891\u2013906 (2009).","journal-title":"Cell"},{"key":"1092_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai, Z., Lin, Y., Lin, P., Zhao, X. & Cui, L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 15, 307 (2024).","journal-title":"Cell Death Dis."},{"key":"1092_CR87","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s42003-021-02539-7","volume":"4","author":"L Martinez-Vidal","year":"2021","unstructured":"Martinez-Vidal, L. et al. Causal contributors to tissue stiffness and clinical relevance in urology. Commun. Biol. 4, 1011 (2021).","journal-title":"Commun. Biol."},{"key":"1092_CR88","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41586-020-2612-2","volume":"584","author":"O Chaudhuri","year":"2020","unstructured":"Chaudhuri, O., Cooper-White, J., Janmey, P. A., Mooney, D. J. & Shenoy, V. B. Effects of extracellular matrix viscoelasticity on cellular behaviour. Nature 584, 535\u2013546 (2020).","journal-title":"Nature"},{"key":"1092_CR89","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/bioengineering7020033","volume":"7","author":"J Sapudom","year":"2020","unstructured":"Sapudom, J. et al. Collagen fibril density modulates macrophage activation and cellular functions during tissue repair. Bioengineering 7, 33\u00a0(2020).","journal-title":"Bioengineering"},{"key":"1092_CR90","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ceb.2015.06.006","volume":"36","author":"R Hallmann","year":"2015","unstructured":"Hallmann, R. et al. The regulation of immune cell trafficking by the extracellular matrix. Curr. Opin. Cell Biol. 36, 54\u201361 (2015).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1092_CR91","doi-asserted-by":"publisher","first-page":"188418","DOI":"10.1016\/j.bbcan.2020.188418","volume":"1874","author":"M Hadden","year":"2020","unstructured":"Hadden, M. et al. Mechanically stressed cancer microenvironment: role in pancreatic cancer progression. Biochim. Biophys. Acta Rev. Cancer 1874, 188418 (2020).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1092_CR92","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"1092_CR93","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"1092_CR94","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544\u2013554 (2017).","journal-title":"Eur. Urol."},{"key":"1092_CR95","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322 (2014).","journal-title":"Nature"},{"key":"1092_CR96","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e25 (2017).","journal-title":"Cell"},{"key":"1092_CR97","first-page":"1","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 1\u201320 (2016).","journal-title":"Genome Biol."},{"key":"1092_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55665-1","volume":"16","author":"A Contreras-Sanz","year":"2025","unstructured":"Contreras-Sanz, A. et al. Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy. Nat. Commun. 16, 1240 (2025).","journal-title":"Nat. Commun."},{"key":"1092_CR99","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-022-01291-7","volume":"15","author":"N Xu","year":"2022","unstructured":"Xu, N. et al. Integrated proteogenomic characterization of urothelial carcinoma of the bladder. J. Hematol. Oncol. 15, 76 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"1092_CR100","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00011-018-1173-4","volume":"67","author":"F Shabani","year":"2018","unstructured":"Shabani, F., Farasat, A., Mahdavi, M. & Gheibi, N. Calprotectin (S100A8\/S100A9): a key protein between inflammation and cancer. Inflamm. Res. 67, 801\u2013812 (2018).","journal-title":"Inflamm. Res."},{"key":"1092_CR101","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00345-013-1227-8","volume":"32","author":"J Ebbing","year":"2014","unstructured":"Ebbing, J. et al. Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder. World J. Urol. 32, 1485\u20131492 (2014).","journal-title":"World J. Urol."},{"key":"1092_CR102","first-page":"181","volume":"7","author":"S Minami","year":"2010","unstructured":"Minami, S. et al. Proteomic study of sera from patients with bladder cancer: usefulness of S100A8 and S100A9 proteins. Cancer Genomics Proteomics 7, 181\u2013189 (2010).","journal-title":"Cancer Genomics Proteomics"},{"key":"1092_CR103","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/cancers15010041","volume":"15","author":"V Smith","year":"2023","unstructured":"Smith, V. et al. Low CD8 T cell counts predict benefit from hypoxia-modifying therapy in muscle-invasive bladder cancer. Cancers 15, 41 (2023).","journal-title":"Cancers"},{"key":"1092_CR104","doi-asserted-by":"publisher","first-page":"101134","DOI":"10.1016\/j.eclinm.2021.101134","volume":"41","author":"F Li","year":"2021","unstructured":"Li, F. et al. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. EClinicalMedicine 41, 101134 (2021).","journal-title":"EClinicalMedicine"},{"key":"1092_CR105","doi-asserted-by":"publisher","first-page":"685370","DOI":"10.3389\/fimmu.2021.685370","volume":"12","author":"R Liu","year":"2021","unstructured":"Liu, R. et al. Influence of tumor immune infiltration on immune checkpoint inhibitor therapeutic efficacy: a computational retrospective study. Front. Immunol. 12, 685370 (2021).","journal-title":"Front. Immunol."},{"key":"1092_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao, Z. et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat. Commun. 14, 5110 (2023).","journal-title":"Nat. Commun."},{"key":"1092_CR107","doi-asserted-by":"publisher","first-page":"1700167","DOI":"10.1002\/pmic.201700167","volume":"18","author":"A Santi","year":"2018","unstructured":"Santi, A., Kugeratski, F. G. & Zanivan, S. Cancer associated fibroblasts: the architects of stroma remodeling. Proteomics 18, 1700167 (2018).","journal-title":"Proteomics"},{"key":"1092_CR108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0448-5","volume":"10","author":"D Von Ahrens","year":"2017","unstructured":"Von Ahrens, D., Bhagat, T. D., Nagrath, D., Maitra, A. & Verma, A. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J. Hematol. Oncol. 10, 1\u20138 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"1092_CR109","doi-asserted-by":"publisher","first-page":"986598","DOI":"10.3389\/fimmu.2023.986598","volume":"14","author":"R Ben\u00edtez","year":"2023","unstructured":"Ben\u00edtez, R., Yu, K., Sirota, M., Malats, N. & Pineda, S. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer. Front. Immunol. 14, 986598 (2023).","journal-title":"Front. Immunol."},{"key":"1092_CR110","doi-asserted-by":"publisher","first-page":"C486","DOI":"10.1152\/ajpcell.00122.2022","volume":"323","author":"JE Str\u00f8bech","year":"2022","unstructured":"Str\u00f8bech, J. E., Giuriatti, P. & Erler, J. T. Neutrophil granulocytes influence on extracellular matrix in cancer progression. Am. J. Physiol. Cell Physiol. 323, C486\u2013C493 (2022).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1092_CR111","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fimmu.2023.1340634","volume":"14","author":"W Du","year":"2024","unstructured":"Du, W., Xia, X., Hu, F. & Yu, J. Extracellular matrix remodeling in the tumor immunity. Front. Immunol. 14, 2023 (2024).","journal-title":"Front. Immunol."},{"key":"1092_CR112","doi-asserted-by":"publisher","first-page":"19609","DOI":"10.1073\/pnas.1908626116","volume":"116","author":"C Tian","year":"2019","unstructured":"Tian, C. et al. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc. Natl Acad. Sci. 116, 19609\u201319618 (2019).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1092_CR113","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","volume":"18","author":"H Jia","year":"2025","unstructured":"Jia, H., Chen, X., Zhang, L. & Chen, M. Cancer associated fibroblasts in cancer development and therapy. J. Hematol. Oncol. 18, 36 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"1092_CR114","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3390\/cancers14051231","volume":"14","author":"RP Czekay","year":"2022","unstructured":"Czekay, R. P., Cheon, D. J., Samarakoon, R., Kutz, S. M. & Higgins, P. J. Cancer-associated fibroblasts: mechanisms of tumor progression and novel therapeutic targets. Cancers 14, 1231\u00a0(2022).","journal-title":"Cancers"},{"key":"1092_CR115","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fcell.2018.00048","volume":"6","author":"JB McCarthy","year":"2018","unstructured":"McCarthy, J. B., El-Ashry, D. & Turley, E. A. Hyaluronan, cancer-associated fibroblasts and the tumor microenvironment in malignant progression. Front. Cell Dev. Biol. 6, 48 (2018).","journal-title":"Front. Cell Dev. Biol."},{"key":"1092_CR116","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.3390\/cancers12113331","volume":"12","author":"A Gordon-Weeks","year":"2020","unstructured":"Gordon-Weeks, A. & Yuzhalin, A. E. Cancer extracellular matrix proteins regulate tumour immunity. Cancers 12, 3331 (2020).","journal-title":"Cancers"},{"key":"1092_CR117","doi-asserted-by":"publisher","first-page":"8243378","DOI":"10.1155\/2021\/8243378","volume":"2021","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. Interplay between extracellular matrix and neutrophils in diseases. J. Immunol. Res. 2021, 8243378 (2021).","journal-title":"J. Immunol. Res."},{"key":"1092_CR118","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-020712-164023","volume":"9","author":"TN Mayadas","year":"2014","unstructured":"Mayadas, T. N., Cullere, X. & Lowell, C. A. The multifaceted functions of neutrophils. Annu. Rev. Pathol. 9, 181\u2013218 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"1092_CR119","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","volume":"303","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532\u20131535 (2004).","journal-title":"Science"},{"key":"1092_CR120","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nri.2017.105","volume":"18","author":"V Papayannopoulos","year":"2018","unstructured":"Papayannopoulos, V. Neutrophil extracellular traps in immunity and disease. Nat. Rev. Immunol. 18, 134\u2013147 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1092_CR121","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3390\/ijms23063218","volume":"23","author":"S Raftopoulou","year":"2022","unstructured":"Raftopoulou, S., Valadez-Cosmes, P., Mihalic, Z. N., Schicho, R. & Kargl, J. Tumor-mediated neutrophil polarization and therapeutic implications. Int. J. Mol. Sci. 23, 3218\u00a0(2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1092_CR122","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","volume":"22","author":"CC Hedrick","year":"2022","unstructured":"Hedrick, C. C. & Malanchi, I. Neutrophils in cancer: heterogeneous and multifaceted. Nat. Rev. Immunol. 22, 173\u2013187 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1092_CR123","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ccell.2016.06.001","volume":"30","author":"S Singhal","year":"2016","unstructured":"Singhal, S. et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell 30, 120\u2013135 (2016).","journal-title":"Cancer Cell"},{"key":"1092_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31675-0","volume":"8","author":"D Powell","year":"2018","unstructured":"Powell, D., Lou, M., Barros Becker, F. & Huttenlocher, A. Cxcr1 mediates recruitment of neutrophils and supports proliferation of tumor-initiating astrocytes in vivo. Sci. Rep. 8, 13285 (2018).","journal-title":"Sci. Rep."},{"key":"1092_CR125","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","volume":"133","author":"MA Giese","year":"2019","unstructured":"Giese, M. A., Hind, L. E. & Huttenlocher, A. Neutrophil plasticity in the tumor microenvironment. Blood 133, 2159\u20132167 (2019).","journal-title":"Blood"},{"key":"1092_CR126","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","volume":"16","author":"ME Shaul","year":"2019","unstructured":"Shaul, M. E. & Fridlender, Z. G. Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 16, 601\u2013620 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1092_CR127","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.it.2019.04.012","volume":"40","author":"C Silvestre-Roig","year":"2019","unstructured":"Silvestre-Roig, C., Fridlender, Z. G., Glogauer, M. & Scapini, P. Neutrophil diversity in health and disease. Trends Immunol. 40, 565\u2013583 (2019).","journal-title":"Trends Immunol."},{"key":"1092_CR128","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fimmu.2020.00532","volume":"11","author":"M Ohms","year":"2020","unstructured":"Ohms, M., M\u00f6ller, S. & Laskay, T. An attempt to polarize human neutrophils toward N1 and N2 phenotypes in vitro. Front. Immunol 11, 532\u00a0(2020).","journal-title":"Front. Immunol"},{"key":"1092_CR129","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1232221","volume":"5","author":"ME Shaul","year":"2016","unstructured":"Shaul, M. E. et al. Tumor-associated neutrophils display a distinct N1 profile following TGF\u03b2 modulation: a transcriptomics analysis of pro-vs. antitumor TANs. Oncoimmunology 5, e1232221 (2016).","journal-title":"Oncoimmunology"},{"key":"1092_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/npjbcancer.2016.9","volume":"2","author":"E Comen","year":"2016","unstructured":"Comen, E. et al. TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients. NPJ Breast Cancer 2, 16009 (2016).","journal-title":"NPJ Breast Cancer"},{"key":"1092_CR131","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/imr.13176","volume":"314","author":"BB Antuamwine","year":"2023","unstructured":"Antuamwine, B. B. et al. N1 versus N2 and PMN-mdsc: a critical appraisal of current concepts on tumor-associated neutrophils and new directions for human oncology. Immunol. Rev. 314, 250\u2013279 (2023).","journal-title":"Immunol. Rev."},{"key":"1092_CR132","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1172\/JCI37223","volume":"120","author":"J Jablonska","year":"2010","unstructured":"Jablonska, J., Leschner, S., Westphal, K., Lienenklaus, S. & Weiss, S. Neutrophils responsive to endogenous IFN-\u03b2 regulate tumor angiogenesis and growth in a mouse tumor model. J. Clin. Investig. 120, 1151\u20131164 (2010).","journal-title":"J. Clin. Investig."},{"key":"1092_CR133","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312855121","volume":"121","author":"W Jing","year":"2024","unstructured":"Jing, W. et al. Tumor\u2013neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression. Proc. Natl Acad. Sci. 121, e2312855121 (2024).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1092_CR134","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.3389\/fimmu.2018.02456","volume":"9","author":"X Wang","year":"2018","unstructured":"Wang, X., Qiu, L., Li, Z., Wang, X. Y. & Yi, H. Understanding the multifaceted role of neutrophils in cancer and autoimmune diseases. Front. Immunol. 9, 2456 (2018).","journal-title":"Front. Immunol."},{"key":"1092_CR135","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","volume":"186","author":"J Gungabeesoon","year":"2023","unstructured":"Gungabeesoon, J. et al. A neutrophil response linked to tumor control in immunotherapy. Cell 186, 1448\u20131464.e20 (2023).","journal-title":"Cell"},{"key":"1092_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.827457","volume":"13","author":"M Yang","year":"2022","unstructured":"Yang, M. et al. Negative effects of stromal neutrophils on t cells reduce survival in resectable urothelial carcinoma of the bladder. Front. Immunol. 13, 827457 (2022).","journal-title":"Front. Immunol."},{"key":"1092_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.602963","volume":"12","author":"E McKenna","year":"2021","unstructured":"McKenna, E. et al. Neutrophils: need for standardized nomenclature. Front. Immunol. 12, 602963\u00a0(2021).","journal-title":"Front. Immunol."},{"key":"1092_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1013672","volume":"13","author":"R Yang","year":"2022","unstructured":"Yang, R. et al. Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer. Front. Pharmacol. 13, 1013672 (2022).","journal-title":"Front. Pharmacol."},{"key":"1092_CR139","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3389\/fimmu.2019.00811","volume":"10","author":"S Ben Mkaddem","year":"2019","unstructured":"Ben Mkaddem, S., Benhamou, M. & Monteiro, R. C. Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools. Front. Immunol. 10, 811 (2019).","journal-title":"Front. Immunol."},{"key":"1092_CR140","doi-asserted-by":"publisher","first-page":"1064484","DOI":"10.3389\/fcell.2022.1064484","volume":"10","author":"CW Yoon","year":"2022","unstructured":"Yoon, C. W., Pan, Y. & Wang, Y. The application of mechanobiotechnology for immuno-engineering and cancer immunotherapy. Front. Cell Dev. Biol. 10, 1064484 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1092_CR141","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1182\/blood-2012-08-451575","volume":"121","author":"PV Afonso","year":"2013","unstructured":"Afonso, P. V., McCann, C. P., Kapnick, S. M. & Parent, C. A. Discoidin domain receptor 2 regulates neutrophil chemotaxis in 3D collagen matrices. Blood 121, 1644\u20131650 (2013).","journal-title":"Blood"},{"key":"1092_CR142","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/jlb.60.2.199","volume":"60","author":"EA Everitt","year":"1996","unstructured":"Everitt, E. A., Malik, A. B. & Hendey, B. Fibronectin enhances the migration rate of human neutrophils in vitro. J. Leukoc. Biol. 60, 199\u2013206 (1996).","journal-title":"J. Leukoc. Biol."},{"key":"1092_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405364","volume":"15","author":"CJ Calo","year":"2024","unstructured":"Calo, C. J., Patil, T., Palizzi, M., Wheeler, N. & Hind, L. E. Collagen concentration regulates neutrophil extravasation and migration in response to infection in an endothelium dependent manner. Front. Immunol. 15, 1405364 (2024).","journal-title":"Front. Immunol."},{"key":"1092_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02634-7","volume":"22","author":"S Wang","year":"2022","unstructured":"Wang, S., Chen, L. & Liu, W. Matrix stiffness-dependent STEAP3 coordinated with PD-L2 identify tumor responding to sorafenib treatment in hepatocellular carcinoma. Cancer Cell Int. 22, 318 (2022).","journal-title":"Cancer Cell Int."},{"key":"1092_CR145","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1182\/blood-2010-11-321125","volume":"118","author":"KM Stroka","year":"2011","unstructured":"Stroka, K. M. & Aranda-Espinoza, H. Endothelial cell substrate stiffness influences neutrophil transmigration via myosin light chain kinase-dependent cell contraction. Blood 118, 1632\u20131640 (2011).","journal-title":"Blood"},{"key":"1092_CR146","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1182\/blood-2015-11-680918","volume":"128","author":"V Monceaux","year":"2016","unstructured":"Monceaux, V. et al. Anoxia and glucose supplementation preserve neutrophil viability and function. Blood 128, 993\u20131002 (2016).","journal-title":"Blood"},{"key":"1092_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120715","volume":"271","author":"JO Abaricia","year":"2021","unstructured":"Abaricia, J. O., Shah, A. H. & Olivares-Navarrete, R. Substrate stiffness induces neutrophil extracellular trap (NET) formation through focal adhesion kinase activation. Biomaterials 271, 120715 (2021).","journal-title":"Biomaterials"},{"key":"1092_CR148","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan, Z. et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol. Cancer 22, 48 (2023).","journal-title":"Mol. Cancer"},{"key":"1092_CR149","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1172\/JCI67484","volume":"123","author":"J Cools-Lartigue","year":"2013","unstructured":"Cools-Lartigue, J. et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Investig. 123, 3446\u20133458 (2013).","journal-title":"J. Clin. Investig."},{"key":"1092_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02036-z","volume":"40","author":"L Ronchetti","year":"2021","unstructured":"Ronchetti, L. et al. Neutrophil extracellular traps in cancer: not only catching microbes. J. Exp. Clin. Cancer Res. 40, 1\u20139 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1092_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109596","volume":"9","author":"KJ Goodall","year":"2014","unstructured":"Goodall, K. J., Poon, I. K., Phipps, S. & Hulett, M. D. Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. PLoS ONE 9, e109596 (2014).","journal-title":"PLoS ONE"},{"key":"1092_CR152","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jim.2007.11.014","volume":"331","author":"N Komatsu","year":"2008","unstructured":"Komatsu, N. et al. Heparanase expression in B16 melanoma cells and peripheral blood neutrophils before and after extravasation detected by novel anti-mouse heparanase monoclonal antibodies. J. Immunol. Methods 331, 82\u201393 (2008).","journal-title":"J. Immunol. Methods"},{"key":"1092_CR153","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S0022-5347(05)65754-0","volume":"166","author":"K Gohji","year":"2001","unstructured":"Gohji, K. et al. Heparanase protein and gene expression in bladder cancer. J. Urol. 166, 1286\u20131290 (2001).","journal-title":"J. Urol."},{"key":"1092_CR154","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1593\/neo.07875","volume":"10","author":"I Shafat","year":"2008","unstructured":"Shafat, I. et al. Clinical significance of urine heparanase in bladder cancer progression. Neoplasia 10, 125\u2013130 (2008).","journal-title":"Neoplasia"},{"key":"1092_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-015-1393-9","volume":"4","author":"A Burnier","year":"2015","unstructured":"Burnier, A. et al. CXCL1 is elevated in the urine of bladder cancer patients. Springerplus 4, 1\u20136 (2015).","journal-title":"Springerplus"},{"key":"1092_CR156","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8721","volume":"8","author":"H Wu","year":"2020","unstructured":"Wu, H., Zhang, X., Han, D., Cao, J. & Tian, J. Tumour-associated macrophages mediate the invasion and metastasis of bladder cancer cells through CXCL8. PeerJ 8, e8721 (2020).","journal-title":"PeerJ"},{"key":"1092_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2490-12-12","volume":"12","author":"V Urquidi","year":"2012","unstructured":"Urquidi, V. et al. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol. 12, 1\u20137 (2012).","journal-title":"BMC Urol."},{"key":"1092_CR158","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1158\/1078-0432.CCR-07-1922","volume":"14","author":"H Kawanishi","year":"2008","unstructured":"Kawanishi, H. et al. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin. Cancer Res. 14, 2579\u20132587 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1092_CR159","first-page":"138","volume":"6","author":"S Ramakrishnan","year":"2018","unstructured":"Ramakrishnan, S. et al. Transcriptional changes associated with in vivo growth of muscle-invasive bladder cancer cell lines in nude mice. Am. J. Clin. Exp. Urol. 6, 138\u2013148 (2018).","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"1092_CR160","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1007\/s13277-013-1604-3","volume":"35","author":"R Pinto-Leite","year":"2014","unstructured":"Pinto-Leite, R. et al. Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer. Tumor Biol. 35, 4599\u20134617 (2014).","journal-title":"Tumor Biol."},{"key":"1092_CR161","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/cells9020291","volume":"9","author":"GE Mandelli","year":"2020","unstructured":"Mandelli, G. E. et al. Tumor infiltrating neutrophils are enriched in basal-type urothelial bladder cancer. Cells 9, 291 (2020).","journal-title":"Cells"},{"key":"1092_CR162","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/cancers11091219","volume":"11","author":"L Benerini Gatta","year":"2019","unstructured":"Benerini Gatta, L. et al. Hyper-activation of STAT3 sustains progression of non-papillary basal-type bladder cancer via FOSL1 regulome. Cancers 11, 1219 (2019).","journal-title":"Cancers"},{"key":"1092_CR163","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1182\/blood-2009-08-240317","volume":"115","author":"H Nguyen-Jackson","year":"2010","unstructured":"Nguyen-Jackson, H., Panopoulos, A. D., Zhang, H., Li, H. S. & Watowich, S. S. STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2 expression and via modulation of CXCR2 signal transduction. Blood 115, 3354\u20133363 (2010).","journal-title":"Blood"},{"key":"1092_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1431-6","volume":"10","author":"C Chen","year":"2019","unstructured":"Chen, C. et al. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT\/NF-\u03baB pathway in colorectal cancer. Cell Death Dis. 10, 178 (2019).","journal-title":"Cell Death Dis."},{"key":"1092_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-018-0936-8","volume":"20","author":"MG Annis","year":"2018","unstructured":"Annis, M. G. et al. Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion. Breast Cancer Res. 20, 1\u201315 (2018).","journal-title":"Breast Cancer Res."},{"key":"1092_CR166","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1142\/S0192415X1450089X","volume":"42","author":"R-C Yang","year":"2014","unstructured":"Yang, R.-C. et al. Davallia bilabiata inhibits TNF-\u03b1-induced adhesion molecules and chemokines by suppressing IKK\/NF-kappa B pathway in vascular endothelial cells. Am. J. Chin. Med. 42, 1411\u20131429 (2014).","journal-title":"Am. J. Chin. Med."},{"key":"1092_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-015-0080-7","volume":"6","author":"C Katanov","year":"2015","unstructured":"Katanov, C. et al. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-\u03b1 and the NF-\u03baB pathway. Stem Cell Res. Ther. 6, 1\u201317 (2015).","journal-title":"Stem Cell Res. Ther."},{"key":"1092_CR168","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.imbio.2012.02.002","volume":"218","author":"F Blengio","year":"2013","unstructured":"Blengio, F. et al. The hypoxic environment reprograms the cytokine\/chemokine expression profile of human mature dendritic cells. Immunobiology 218, 76\u201389 (2013).","journal-title":"Immunobiology"},{"key":"1092_CR169","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/nar\/gkr978","volume":"40","author":"K Wollenick","year":"2012","unstructured":"Wollenick, K. et al. Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling. Nucleic Acids Res. 40, 1928\u20131943 (2012).","journal-title":"Nucleic Acids Res."},{"key":"1092_CR170","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202205613","volume":"10","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. ETV4 mediated tumor-associated neutrophil infiltration facilitates lymphangiogenesis and lymphatic metastasis of bladder cancer. Adv. Sci. 10, e2205613 (2023).","journal-title":"Adv. Sci."},{"key":"1092_CR171","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.4049\/jimmunol.170.6.3369","volume":"170","author":"A Li","year":"2003","unstructured":"Li, A., Dubey, S., Varney, M. L., Dave, B. J. & Singh, R. K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 170, 3369\u20133376 (2003).","journal-title":"J. Immunol."},{"key":"1092_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1022380","volume":"13","author":"F Zhang","year":"2022","unstructured":"Zhang, F. et al. The role of extracellular traps in ischemia reperfusion injury. Front. Immunol. 13, 1022380 (2022).","journal-title":"Front. Immunol."},{"key":"1092_CR173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000639","volume":"5","author":"CF Urban","year":"2009","unstructured":"Urban, C. F. et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 5, e1000639 (2009).","journal-title":"PLoS Pathog."},{"key":"1092_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01112-5","volume":"21","author":"J Li","year":"2023","unstructured":"Li, J. et al. Neutrophil extracellular traps induced by the hypoxic microenvironment in gastric cancer augment tumour growth. Cell Commun. Signal. 21, 86 (2023).","journal-title":"Cell Commun. Signal."},{"key":"1092_CR175","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","volume":"21","author":"TR Cox","year":"2021","unstructured":"Cox, T. R. The matrix in cancer. Nat. Rev. Cancer 21, 217\u2013238 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1092_CR176","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","volume":"18","author":"Q Hu","year":"2025","unstructured":"Hu, Q., Zhu, Y., Mei, J., Liu, Y. & Zhou, G. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J. Hematol. Oncol. 18, 65 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"1092_CR177","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1158\/0008-5472.CAN-17-0348","volume":"78","author":"C Blattner","year":"2018","unstructured":"Blattner, C. et al. CCR5+ myeloid-derived suppressor cells are enriched and activated in melanoma lesions. Cancer Res. 78, 157\u2013167 (2018).","journal-title":"Cancer Res."},{"key":"1092_CR178","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells. J. Exp. Med. 208, 2005\u20132016 (2011).","journal-title":"J. Exp. Med."},{"key":"1092_CR179","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1172\/JCI77053","volume":"124","author":"EB Eruslanov","year":"2014","unstructured":"Eruslanov, E. B. et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J. Clin. Investig. 124, 5466\u20135480 (2014).","journal-title":"J. Clin. Investig."},{"key":"1092_CR180","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/126954","volume":"2014","author":"CE de Oliveira","year":"2014","unstructured":"de Oliveira, C. E. et al. CC chemokine receptor 5: the interface of host immunity and cancer. Dis. Markers 2014, 126954 (2014).","journal-title":"Dis. Markers"},{"key":"1092_CR181","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3118","volume":"356","author":"E Cai","year":"2017","unstructured":"Cai, E. et al. Visualizing dynamic microvillar search and stabilization during ligand detection by T cells. Science 356, eaal3118 (2017).","journal-title":"Science"},{"key":"1092_CR182","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/cancers9110153","volume":"9","author":"M Reina","year":"2017","unstructured":"Reina, M. & Espel, E. Role of LFA-1 and ICAM-1 in cancer. Cancers 9, 153 (2017).","journal-title":"Cancers"},{"key":"1092_CR183","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nri2808","volume":"10","author":"RA Flavell","year":"2010","unstructured":"Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Lim\u00f3n, P. The polarization of immune cells in the tumour environment by TGF\u03b2. Nat. Rev. Immunol. 10, 554\u2013567 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1092_CR184","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","volume":"29","author":"N Halama","year":"2016","unstructured":"Halama, N. et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell 29, 587\u2013601 (2016).","journal-title":"Cancer Cell"},{"key":"1092_CR185","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s13402-018-0415-3","volume":"42","author":"A Pervaiz","year":"2019","unstructured":"Pervaiz, A. et al. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer. Cell. Oncol. 42, 93\u2013106 (2019).","journal-title":"Cell. Oncol."},{"key":"1092_CR186","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3390\/ijms19051477","volume":"19","author":"D Aldinucci","year":"2018","unstructured":"Aldinucci, D. & Casagrande, N. Inhibition of the CCL5\/CCR5 Axis against the progression of gastric cancer. Int. J. Mol. Sci. 19, 1477 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1092_CR187","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1158\/0008-5472.CAN-16-2913","volume":"77","author":"Y Ban","year":"2017","unstructured":"Ban, Y. et al. Targeting autocrine CCL5\u2013CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity. Cancer Res. 77, 2857\u20132868 (2017).","journal-title":"Cancer Res."},{"key":"1092_CR188","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1165\/rcmb.2008-0139OC","volume":"42","author":"J Roman","year":"2010","unstructured":"Roman, J. et al. T-cell activation under hypoxic conditions enhances IFN-\u03b3 secretion. Am. J. Respir. Cell Mol. Biol. 42, 123\u2013128 (2010).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1092_CR189","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540\u20131554.e12 (2016).","journal-title":"Cell"},{"key":"1092_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1100317","volume":"13","author":"H Deng","year":"2023","unstructured":"Deng, H. et al. An IFN-\u03b3-related signature predicts prognosis and immunotherapy response in bladder cancer: results from real-world cohorts. Front. Genet. 13, 1100317 (2023).","journal-title":"Front. Genet."},{"key":"1092_CR191","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.omto.2021.11.006","volume":"23","author":"JL Green","year":"2021","unstructured":"Green, J. L. et al. Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance. Mol. Ther. Oncolytics 23, 547\u2013559 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1092_CR192","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/cancers16030598","volume":"16","author":"Y Park","year":"2024","unstructured":"Park, Y. et al. The matrix stiffness coordinates the cell proliferation and PD-L1 expression via YAP in lung adenocarcinoma. Cancers 16, 598\u00a0(2024).","journal-title":"Cancers"},{"key":"1092_CR193","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.bbrc.2017.12.115","volume":"495","author":"A Miyazawa","year":"2018","unstructured":"Miyazawa, A. et al. Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. Biochem. Biophys. Res. Commun. 495, 2344\u20132349 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1092_CR194","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.imlet.2010.01.006","volume":"129","author":"PE Bankey","year":"2010","unstructured":"Bankey, P. E. et al. Cytokine induced expression of programmed death ligands in human neutrophils. Immunol. Lett. 129, 100\u2013107 (2010).","journal-title":"Immunol. Lett."},{"key":"1092_CR195","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072249","volume":"8","author":"S de Kleijn","year":"2013","unstructured":"de Kleijn, S. et al. IFN-\u03b3-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLoS ONE 8, e72249 (2013).","journal-title":"PLoS ONE"},{"key":"1092_CR196","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781\u2013790 (2014).","journal-title":"J. Exp. Med."},{"key":"1092_CR197","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2017.12.007","volume":"48","author":"A Glasner","year":"2018","unstructured":"Glasner, A. et al. NKp46 receptor-mediated interferon-\u03b3 production by natural killer cells increases fibronectin 1 to alter tumor architecture and control metastasis. Immunity 48, 107\u2013119.e104 (2018).","journal-title":"Immunity"},{"key":"1092_CR198","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-015-0256-0","volume":"34","author":"G He","year":"2015","unstructured":"He, G. et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1\/PD-1 signalling pathway in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 34, 1\u201311 (2015).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1092_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27303-7","volume":"12","author":"C Hinterleitner","year":"2021","unstructured":"Hinterleitner, C. et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat. Commun. 12, 7005 (2021).","journal-title":"Nat. Commun."},{"key":"1092_CR200","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027\u20131034 (2000).","journal-title":"J. Exp. Med."},{"key":"1092_CR201","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4161\/onci.21335","volume":"1","author":"L Zitvogel","year":"2012","unstructured":"Zitvogel, L. & Kroemer, G. Targeting PD-1\/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1, 1223\u20131225 (2012).","journal-title":"Oncoimmunology"},{"key":"1092_CR202","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1136\/gutjnl-2016-313075","volume":"66","author":"T-t Wang","year":"2017","unstructured":"Wang, T. -t et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut 66, 1900\u20131911 (2017).","journal-title":"Gut"},{"key":"1092_CR203","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"X Pang","year":"2023","unstructured":"Pang, X. et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct. Target Ther. 8, 1 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1092_CR204","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00031-20","volume":"88","author":"K Yuki","year":"2020","unstructured":"Yuki, K. & Hou, L. Role of \u03b22 integrins in neutrophils and sepsis. Infect. Immun. 88, e00031-20\u00a0(2020).","journal-title":"Infect. Immun."},{"key":"1092_CR205","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1152\/physrev.00062.2021","volume":"103","author":"M Herre","year":"2023","unstructured":"Herre, M., Cedervall, J., Mackman, N. & Olsson, A.-K. Neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases. Physiol. Rev. 103, 277\u2013312 (2023).","journal-title":"Physiol. Rev."},{"key":"1092_CR206","doi-asserted-by":"publisher","first-page":"937565","DOI":"10.3389\/fimmu.2022.937565","volume":"13","author":"J Zhao","year":"2022","unstructured":"Zhao, J. & Jin, J. Neutrophil extracellular traps: new players in cancer research. Front. Immunol. 13, 937565 (2022).","journal-title":"Front. Immunol."},{"key":"1092_CR207","doi-asserted-by":"publisher","first-page":"1019967","DOI":"10.3389\/fimmu.2022.1019967","volume":"13","author":"Q Li","year":"2022","unstructured":"Li, Q., Chen, W., Li, Q., Mao, J. & Chen, X. A novel neutrophil extracellular trap signature to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma. Front. Immunol. 13, 1019967 (2022).","journal-title":"Front. Immunol."},{"key":"1092_CR208","doi-asserted-by":"publisher","first-page":"17864","DOI":"10.18632\/aging.203289","volume":"13","author":"C Fang","year":"2021","unstructured":"Fang, C. et al. A innovative prognostic symbol based on neutrophil extracellular traps (NETs)-related lncRNA signature in non-small-cell lung cancer. Aging 13, 17864 (2021).","journal-title":"Aging"},{"key":"1092_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1047367","volume":"13","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Identification of renal ischemia reperfusion injury subtypes and predictive strategies for delayed graft function and graft survival based on neutrophil extracellular trap-related genes. Front. Immunol. 13, 1047367 (2022).","journal-title":"Front. Immunol."},{"key":"1092_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47824-z","volume":"13","author":"C Guo","year":"2023","unstructured":"Guo, C. et al. Identification of bladder cancer subtypes and predictive model for prognosis, immune features, and immunotherapy based on neutrophil extracellular trap-related genes. Sci. Rep. 13, 20791 (2023).","journal-title":"Sci. Rep."},{"key":"1092_CR211","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","volume":"48","author":"LK Smith","year":"2018","unstructured":"Smith, L. K. et al. Interleukin-10 directly inhibits CD8+ T cell function by enhancing N-glycan branching to decrease antigen sensitivity. Immunity 48, 299\u2013312.e5 (2018).","journal-title":"Immunity"},{"key":"1092_CR212","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3389\/fimmu.2019.00842","volume":"10","author":"K Kumawat","year":"2019","unstructured":"Kumawat, K. et al. LAIR-1 limits neutrophilic airway inflammation. Front. Immunol. 10, 842 (2019).","journal-title":"Front. Immunol."},{"key":"1092_CR213","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3389\/fimmu.2019.02088","volume":"10","author":"T Gomes","year":"2019","unstructured":"Gomes, T. et al. IL-1\u03b2 blockade attenuates thrombosis in a neutrophil extracellular trap-dependent breast cancer model. Front. Immunol. 10, 2088 (2019).","journal-title":"Front. Immunol."},{"key":"1092_CR214","doi-asserted-by":"publisher","first-page":"6252138","DOI":"10.1155\/2019\/6252138","volume":"2019","author":"M Gonzalez-Aparicio","year":"2019","unstructured":"Gonzalez-Aparicio, M. & Alfaro, C. Influence of interleukin-8 and neutrophil extracellular trap (NET) formation in the tumor microenvironment: is there a pathogenic role? J. Immunol. Res. 2019, 6252138 (2019).","journal-title":"J. Immunol. Res."},{"key":"1092_CR215","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1171065","volume":"14","author":"R Herranz","year":"2023","unstructured":"Herranz, R. et al. Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro. Front. Immunol. 14, 1171065 (2023).","journal-title":"Front. Immunol."},{"key":"1092_CR216","doi-asserted-by":"publisher","first-page":"15880","DOI":"10.1073\/pnas.1005743107","volume":"107","author":"TA Fuchs","year":"2010","unstructured":"Fuchs, T. A. et al. Extracellular DNA traps promote thrombosis. Proc. Natl Acad. Sci. 107, 15880\u201315885 (2010).","journal-title":"Proc. Natl Acad. Sci."},{"key":"1092_CR217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-021-00708-z","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. The regulatory mechanism of neutrophil extracellular traps in cancer biological behavior. Cell Biosci. 11, 1\u201313 (2021).","journal-title":"Cell Biosci."},{"key":"1092_CR218","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/path.5753","volume":"255","author":"CE de Andrea","year":"2021","unstructured":"de Andrea, C. E. et al. Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8. J. Pathol. 255, 190\u2013201 (2021).","journal-title":"J. Pathol."},{"key":"1092_CR219","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23086-z","volume":"12","author":"S Shinde-Jadhav","year":"2021","unstructured":"Shinde-Jadhav, S. et al. Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer. Nat. Commun. 12, 2776 (2021).","journal-title":"Nat. Commun."},{"key":"1092_CR220","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138581","volume":"5","author":"A Ugolini","year":"2020","unstructured":"Ugolini, A. et al. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. JCI Insight 5, e138581\u00a0(2020).","journal-title":"JCI Insight"},{"key":"1092_CR221","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc745","volume":"2","author":"M Egeblad","year":"2002","unstructured":"Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161\u2013174 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"1092_CR222","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc.2016.115","volume":"17","author":"HW Jackson","year":"2017","unstructured":"Jackson, H. W., Defamie, V., Waterhouse, P. & Khokha, R. TIMPs: versatile extracellular regulators in cancer. Nat. Rev. Cancer 17, 38\u201353 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1092_CR223","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52\u201367 (2010).","journal-title":"Cell"},{"key":"1092_CR224","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3389\/fimmu.2016.00518","volume":"7","author":"K Branitzki-Heinemann","year":"2016","unstructured":"Branitzki-Heinemann, K. et al. Formation of neutrophil extracellular traps under low oxygen level. Front. Immunol. 7, 518 (2016).","journal-title":"Front. Immunol."},{"key":"1092_CR225","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1111\/febs.15476","volume":"287","author":"FR Hammond","year":"2020","unstructured":"Hammond, F. R., Lewis, A. & Elks, P. M. If it\u2019s not one thing, HIF\u2019s another: immunoregulation by hypoxia inducible factors in disease. FEBS J. 287, 3907\u20133916 (2020).","journal-title":"FEBS J."},{"key":"1092_CR226","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1182\/blood-2012-01-405993","volume":"120","author":"AM McInturff","year":"2012","unstructured":"McInturff, A. M. et al. Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 \u03b1. Blood 120, 3118\u20133125 (2012).","journal-title":"Blood"},{"key":"1092_CR227","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1593\/neo.10344","volume":"12","author":"SM Kakkad","year":"2010","unstructured":"Kakkad, S. M. et al. Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia 12, 608\u2013617 (2010).","journal-title":"Neoplasia"},{"key":"1092_CR228","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-017-9175-8","volume":"14","author":"ER Holthoff","year":"2017","unstructured":"Holthoff, E. R. et al. Vulvar squamous cell carcinoma aggressiveness is associated with differential expression of collagen and STAT1. Clin. Proteomics 14, 40 (2017).","journal-title":"Clin. Proteomics"},{"key":"1092_CR229","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/osi2.1182","volume":"21","author":"K Uzawa","year":"2024","unstructured":"Uzawa, K., Kasamatsu, A. & Yamauchi, M. Collagen cross-linking in oral cancer. Oral. Sci. Int. 21, 3\u201314 (2024).","journal-title":"Oral. Sci. Int."},{"key":"1092_CR230","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/onc.2016.225","volume":"36","author":"S Chouaib","year":"2017","unstructured":"Chouaib, S., Noman, M., Kosmatopoulos, K. & Curran, M. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 36, 439\u2013445 (2017).","journal-title":"Oncogene"},{"key":"1092_CR231","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.clon.2021.03.001","volume":"33","author":"T Lodhi","year":"2021","unstructured":"Lodhi, T., Song, Y. P., West, C., Hoskin, P. & Choudhury, A. Hypoxia and its modification in bladder cancer: current and future perspectives. Clin. Oncol. 33, 376\u2013390 (2021).","journal-title":"Clin. Oncol."},{"key":"1092_CR232","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1092_CR233","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.3390\/cancers13225724","volume":"13","author":"DJ Benjamin","year":"2021","unstructured":"Benjamin, D. J. & Lyou, Y. Advances in immunotherapy and the TGF-\u03b2 resistance pathway in metastatic bladder cancer. Cancers 13, 5724\u00a0(2021).","journal-title":"Cancers"},{"key":"1092_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100755","volume":"31","author":"M Shou","year":"2023","unstructured":"Shou, M., Zhou, H. & Ma, L. New advances in cancer therapy targeting TGF-\u03b2 signaling pathways. Mol. Ther. Oncolytics 31, 100755 (2023).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1092_CR235","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04349280 (2024)."},{"key":"1092_CR236","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav2437","volume":"5","author":"MM Tu","year":"2019","unstructured":"Tu, M. M. et al. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci. Adv. 5, eaav2437 (2019).","journal-title":"Sci. Adv."},{"key":"1092_CR237","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1593\/neo.08432","volume":"10","author":"PD Williams","year":"2008","unstructured":"Williams, P. D., Lee, J. K. & Theodorescu, D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia 10, 838\u2013846 (2008).","journal-title":"Neoplasia"},{"key":"1092_CR238","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41388-017-0099-6","volume":"37","author":"D Fantini","year":"2018","unstructured":"Fantini, D. et al. A carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene 37, 1911\u20131925 (2018).","journal-title":"Oncogene"},{"key":"1092_CR239","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914895","volume":"24","author":"AVA Mariadoss","year":"2023","unstructured":"Mariadoss, A. V. A. & Wang, C. Z. Exploring the cellular and molecular mechanism of discoidin domain receptors (DDR1 and DDR2) in bone formation, regeneration, and its associated disease conditions. Int. J. Mol. Sci. 24, 14895\u00a0(2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1092_CR240","doi-asserted-by":"publisher","first-page":"S649","DOI":"10.1016\/j.annonc.2023.09.2976","volume":"34","author":"S Sen","year":"2023","unstructured":"Sen, S. et al. 1079TiP a phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies. Ann. Oncol. 34, S649\u2013S650 (2023).","journal-title":"Ann. Oncol."},{"key":"1092_CR241","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05753722 (2025)."},{"key":"1092_CR242","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S1074-7613(00)80530-0","volume":"7","author":"L Meyaard","year":"1997","unstructured":"Meyaard, L. et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 7, 283\u2013290 (1997).","journal-title":"Immunity"},{"key":"1092_CR243","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jaci.2017.08.031","volume":"141","author":"RJ Geerdink","year":"2018","unstructured":"Geerdink, R. J. et al. LAIR-1 limits neutrophil extracellular trap formation in viral bronchiolitis. J. Allergy Clin. Immunol. 141, 811\u2013814 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1092_CR244","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18298-8","volume":"11","author":"DH Peng","year":"2020","unstructured":"Peng, D. H. et al. Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat. Commun. 11, 4520 (2020).","journal-title":"Nat. Commun."},{"key":"1092_CR245","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.62927","volume":"10","author":"MIP Ramos","year":"2021","unstructured":"Ramos, M. I. P. et al. Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction. Elife 10, e62927 (2021).","journal-title":"Elife"},{"key":"1092_CR246","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.4049\/jimmunol.180.3.1662","volume":"180","author":"RJ Lebbink","year":"2008","unstructured":"Lebbink, R. J. et al. The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen\/LAIR-1 inhibitory immune interaction1. J. Immunol. 180, 1662\u20131669 (2008).","journal-title":"J. Immunol."},{"key":"1092_CR247","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf121","author":"T Giridharan","year":"2025","unstructured":"Giridharan, T. et al. NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression. J. Immunol. https:\/\/doi.org\/10.1093\/jimmun\/vkaf121 (2025).","journal-title":"J. Immunol."},{"key":"1092_CR248","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3390\/cells10051255","volume":"10","author":"K Miyake","year":"2021","unstructured":"Miyake, K. & Karasuyama, H. The role of trogocytosis in the modulation of immune cell functions. Cells 10, 1255\u00a0(2021).","journal-title":"Cells"},{"key":"1092_CR249","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.matbio.2024.07.003","volume":"133","author":"J Guillard","year":"2024","unstructured":"Guillard, J. & Schw\u00f6rer, S. Metabolic control of collagen synthesis. Matrix Biol. 133, 43\u201356 (2024).","journal-title":"Matrix Biol."},{"key":"1092_CR250","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/genes14040933","volume":"14","author":"A Paneque","year":"2023","unstructured":"Paneque, A., Fortus, H., Zheng, J., Werlen, G. & Jacinto, E. The hexosamine biosynthesis pathway: regulation and function. Genes 14, 993\u00a0(2023).","journal-title":"Genes"},{"key":"1092_CR251","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1172\/JCI127515","volume":"130","author":"NS Sharma","year":"2020","unstructured":"Sharma, N. S. et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J. Clin. Investig. 130, 451\u2013465 (2020).","journal-title":"J. Clin. Investig."},{"key":"1092_CR252","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/cancers11050692","volume":"11","author":"E Cruz da Silva","year":"2019","unstructured":"Cruz da Silva, E., Dontenwill, M., Choulier, L. & Lehmann, M. Role of integrins in resistance to therapies targeting growth facto receptors in cancer. Cancers 11, 692\u00a0(2019).","journal-title":"Cancers"},{"key":"1092_CR253","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.3390\/ijms26073143","volume":"26","author":"Y Kariya","year":"2025","unstructured":"Kariya, Y. & Nishita, M. Integrins in cancer drug resistance: molecular mechanisms and clinical implications. Int. J. Mol. Sci. 26, 3143 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1092_CR254","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04152018 (2025)."},{"key":"1092_CR255","unstructured":"BCAN. Pharmacokinetics, and pharmacodynamics of escalating doses of pf-06940434 in patients with advanced or metastatic solid tumors. BCAN https:\/\/bcan.org\/clinicaltrials\/study-of-pf-06940434-in-patients-with-advanced-or-metastatic-solid-tumors\/#official (2019)."},{"key":"1092_CR256","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006749","volume":"11","author":"KA Reil","year":"2023","unstructured":"Reil, K. A. et al. Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors. J. Immunother. Cancer 11, e006749\u00a0(2023).","journal-title":"J. Immunother. Cancer"},{"key":"1092_CR257","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2022.40.6_suppl.488","volume":"40","author":"SP Lerner","year":"2022","unstructured":"Lerner, S. P. et al. VAX014 for instillation in subjects with nonmuscle-invasive bladder cancer. J. Clin. Oncol. 40, 488\u2013488 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1092_CR258","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03854721 (2023)."},{"key":"1092_CR259","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1464-410X.2010.09534.x","volume":"107","author":"HM Behnsawy","year":"2011","unstructured":"Behnsawy, H. M. et al. Expression of integrin proteins in non-muscle-invasive bladder cancer: significance of intravesical recurrence after transurethral resection. BJU Int. 107, 240\u2013246 (2011).","journal-title":"BJU Int."},{"key":"1092_CR260","first-page":"1016","volume":"144","author":"M Liebert","year":"1994","unstructured":"Liebert, M., Washington, R., Stein, J., Wedemeyer, G. & Grossman, H. B. Expression of the VLA beta 1 integrin family in bladder cancer. Am. J. Pathol. 144, 1016\u20131022 (1994).","journal-title":"Am. J. Pathol."},{"key":"1092_CR261","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/bjc.1996.57","volume":"73","author":"T Saito","year":"1996","unstructured":"Saito, T., Kimura, M., Kawasaki, T., Sato, S. & Tomita, Y. Correlation between integrin alpha 5 expression and the malignant phenotype of transitional cell carcinoma. Br. J. Cancer 73, 327\u2013331 (1996).","journal-title":"Br. J. Cancer"},{"key":"1092_CR262","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/bs.apha.2017.08.002","volume":"81","author":"X Wang","year":"2018","unstructured":"Wang, X. & Khalil, R. A. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv. Pharmacol. 81, 241\u2013330 (2018).","journal-title":"Adv. Pharmacol."},{"key":"1092_CR263","first-page":"1101","volume":"4","author":"J Nemunaitis","year":"1998","unstructured":"Nemunaitis, J. et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. 4, 1101\u20131109 (1998).","journal-title":"Clin. Cancer Res."},{"key":"1092_CR264","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1023\/A:1023047431869","volume":"22","author":"M Pavlaki","year":"2003","unstructured":"Pavlaki, M. & Zucker, S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 22, 177\u2013203 (2003).","journal-title":"Cancer Metastasis Rev."},{"key":"1092_CR265","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1126\/science.1067100","volume":"295","author":"LM Coussens","year":"2002","unstructured":"Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer \u2014 trials and tribulations. Science 295, 2387\u20132392 (2002).","journal-title":"Science"},{"key":"1092_CR266","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/23523735241296763","volume":"10","author":"MJ Moussa","year":"2024","unstructured":"Moussa, M. J. et al. Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: systematic review and meta-analysis. Bladder Cancer 10, 300\u2013312 (2024).","journal-title":"Bladder Cancer"},{"key":"1092_CR267","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot, Y. et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 389, 1961\u20131971 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1092_CR268","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03390504 (2025)."},{"key":"1092_CR269","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.3390\/cancers13225681","volume":"11","author":"AM Chioni","year":"2021","unstructured":"Chioni, A. M. & Grose, R. P. Biological significance and targeting of the FGFR axis in cancer. Cancers 11, 5681\u00a0(2021).","journal-title":"Cancers"},{"key":"1092_CR270","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes, F. M. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10, 2298\u20132308 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"1092_CR271","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134552","volume":"10","author":"YW Kim","year":"2015","unstructured":"Kim, Y. W. et al. The c-MET network as novel prognostic marker for predicting bladder cancer patients with an increased risk of developing aggressive disease. PLoS ONE 10, e0134552 (2015).","journal-title":"PLoS ONE"},{"key":"1092_CR272","doi-asserted-by":"publisher","first-page":"169.e7","DOI":"10.1016\/j.urology.2016.12.006","volume":"101","author":"T Shintani","year":"2017","unstructured":"Shintani, T. et al. The involvement of hepatocyte growth factor-MET-matrix metalloproteinase 1 signaling in bladder cancer invasiveness and proliferation. Effect of the MET inhibitor, cabozantinib (XL184), on bladder cancer cells. Urology 101, 169.e7\u2013169.e13 (2017).","journal-title":"Urology"},{"key":"1092_CR273","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.3390\/cancers15092626","volume":"15","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. c-Met mediated cytokine network promotes brain metastasis of breast cancer by remodeling neutrophil activities. Cancers 15, 2626 (2023).","journal-title":"Cancers"},{"key":"1092_CR274","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/1078-0432.CCR-21-2517","volume":"28","author":"R Esteban-Fabr\u00f3","year":"2022","unstructured":"Esteban-Fabr\u00f3, R. et al. Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma. Clin. Cancer Res. 28, 2449\u20132460 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1092_CR275","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-16-0778","volume":"7","author":"A Patnaik","year":"2017","unstructured":"Patnaik, A. et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov. 7, 750\u2013765 (2017).","journal-title":"Cancer Discov."},{"key":"1092_CR276","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01688999 (2022)."},{"key":"1092_CR277","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1470-2045(20)30202-3","volume":"21","author":"AB Apolo","year":"2020","unstructured":"Apolo, A. B. et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol. 21, 1099\u20131109 (2020).","journal-title":"Lancet Oncol."},{"key":"1092_CR278","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1200\/JCO.23.02233","volume":"42","author":"AB Apolo","year":"2024","unstructured":"Apolo, A. B. et al. Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced\/metastatic genitourinary tumors. J. Clin. Oncol. 42, 3033\u20133046 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1092_CR279","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02496208 (2025)."},{"key":"1092_CR280","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.clgc.2021.04.001","volume":"19","author":"L Marandino","year":"2021","unstructured":"Marandino, L. et al. Cabozantinib plus durvalumab in patients with advanced urothelial carcinoma after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial. Clin. Genitourin. Cancer 19, 457\u2013465 (2021).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1092_CR281","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03824691 (2021)."},{"key":"1092_CR282","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3389\/fimmu.2019.02155","volume":"10","author":"P Lecot","year":"2019","unstructured":"Lecot, P. et al. Neutrophil heterogeneity in cancer: from biology to therapies. Front. Immunol. 10, 2155 (2019).","journal-title":"Front. Immunol."},{"key":"1092_CR283","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2024.42.16_suppl.9508","volume":"42","author":"SP Patel","year":"2024","unstructured":"Patel, S. P. et al. Safety and efficacy of first-in-class CXCR1\/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti\u2013PD-1 therapy. J. Clin. Oncol. 42, 9508\u20139508 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1092_CR284","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03161431 (2024)."},{"key":"1092_CR285","doi-asserted-by":"publisher","first-page":"TPS3638","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3638","volume":"40","author":"B Johnson","year":"2022","unstructured":"Johnson, B. et al. STOPTRAFFIC-1: a phase I\/II trial of SX-682 in combination with nivolumab for refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J. Clin. Oncol. 40, TPS3638\u2013TPS3638 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1092_CR286","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04599140 (2025)."},{"key":"1092_CR287","doi-asserted-by":"publisher","first-page":"TPS631","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS631","volume":"40","author":"RF Dunne","year":"2022","unstructured":"Dunne, R. F. et al. A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma. J. Clin. Oncol. 40, TPS631\u2013TPS631 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1092_CR288","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04477343 (2025)."},{"key":"1092_CR289","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10637-023-01410-2","volume":"42","author":"AJ Armstrong","year":"2024","unstructured":"Armstrong, A. J. et al. CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Invest. New Drugs 42, 145\u2013159 (2024).","journal-title":"Invest. New Drugs"},{"key":"1092_CR290","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03473925 (2024)."},{"key":"1092_CR291","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","volume":"7","author":"M Bilusic","year":"2019","unstructured":"Bilusic, M. et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J. Immunother. Cancer 7, 240 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1092_CR292","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04848116 (2025)."},{"key":"1092_CR293","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.3390\/cancers13215333","volume":"13","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Neutrophils extracellular traps inhibition improves PD-1 blockade immunotherapy in colorectal cancer. Cancers 13, 5333 (2021).","journal-title":"Cancers"},{"key":"1092_CR294","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/2159-8290.CD-24-1056","volume":"15","author":"A Ugolini","year":"2025","unstructured":"Ugolini, A. et al. Functional reprogramming of neutrophils within the brain tumor microenvironment by hypoxia-driven histone lactylation. Cancer Discov. 15, 1270\u20131296\u00a0(2025).","journal-title":"Cancer Discov."},{"key":"1092_CR295","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2024.100843","volume":"23","author":"HJ Lee","year":"2024","unstructured":"Lee, H. J. et al. Proteomic heterogeneity of the extracellular matrix identifies histologic subtype-specific fibroblast in gastric cancer. Mol. Cell Proteomics 23, 100843 (2024).","journal-title":"Mol. Cell Proteomics"},{"key":"1092_CR296","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.3390\/cancers13194932","volume":"13","author":"AM Wandmacher","year":"2021","unstructured":"Wandmacher, A. M., Mehdorn, A. S., Sebens, S. & Group Young Researchers In Inflammatory Carcinogenesis. The heterogeneity of the tumor microenvironment as essential determinant of development, progression and therapy response of pancreatic cancer. Cancers 13, 4932\u00a0(2021).","journal-title":"Cancers"},{"key":"1092_CR297","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00262-025-04049-5","volume":"74","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Unraveling the complex role of tumor-associated neutrophils within solid tumors. Cancer Immunol. Immunother. 74, 210 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"1092_CR298","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fimmu.2024.1341390","volume":"15","author":"I Di Ceglie","year":"2024","unstructured":"Di Ceglie, I. et al. Immune cell networking in solid tumors: focus on macrophages and neutrophils. Front. Immunol. 15, 2024 (2024).","journal-title":"Front. Immunol."},{"key":"1092_CR299","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ebiom.2019.10.058","volume":"50","author":"B-N Song","year":"2019","unstructured":"Song, B.-N. et al. Identification of an immunotherapy-responsive molecular subtype of bladder cancer. EBioMedicine 50, 238\u2013245 (2019).","journal-title":"EBioMedicine"},{"key":"1092_CR300","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-020-02649-x","volume":"70","author":"R Cao","year":"2021","unstructured":"Cao, R., Yuan, L., Ma, B., Wang, G. & Tian, Y. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). Cancer Immunol. Immunother. 70, 1\u201318 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"1092_CR301","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.3390\/cancers15194886","volume":"15","author":"B Rani","year":"2023","unstructured":"Rani, B., Ignatz-Hoover, J. J., Rana, P. S. & Driscoll, J. J. Current and emerging strategies to treat urothelial carcinoma. Cancers 15, 4886 (2023).","journal-title":"Cancers"},{"key":"1092_CR302","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.3390\/ijms25126750","volume":"25","author":"E German\u00e0","year":"2024","unstructured":"German\u00e0, E. et al. Programmed cell death ligand 1 (PD-L1) immunohistochemical expression in advanced urothelial bladder carcinoma: an updated review with clinical and pathological implications. Int. J. Mol. Sci. 25, 6750\u00a0(2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1092_CR303","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.21.01003","volume":"39","author":"TL Rose","year":"2021","unstructured":"Rose, T. L. et al. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J. Clin. Oncol. 39, 3140\u20133148 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1092_CR304","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02690558 (2025)."},{"key":"1092_CR305","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48480-1","volume":"15","author":"W Beckabir","year":"2024","unstructured":"Beckabir, W. et al. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nat. Commun. 15, 4448 (2024).","journal-title":"Nat. Commun."},{"key":"1092_CR306","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1453278","volume":"14","author":"M Ahangar","year":"2024","unstructured":"Ahangar, M., Mahjoubi, F. & Mowla, S. J. Bladder cancer biomarkers: current approaches and future directions. Front. Oncol. 14, 1453278 (2024).","journal-title":"Front. Oncol."},{"key":"1092_CR307","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.3390\/cancers14194706","volume":"14","author":"S Baldari","year":"2022","unstructured":"Baldari, S., Di Modugno, F., Nistic\u00f2, P. & Toietta, G. Strategies for efficient targeting of tumor collagen for cancer therapy. Cancers 14, 4706\u00a0(2022).","journal-title":"Cancers"},{"key":"1092_CR308","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1225483","volume":"13","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy. Front. Oncol. 13, 1225483 (2023).","journal-title":"Front. Oncol."},{"key":"1092_CR309","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau3259","volume":"11","author":"J Ishihara","year":"2019","unstructured":"Ishihara, J. et al. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci. Transl. Med. 11, eaau3259 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1092_CR310","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2614","volume":"11","author":"N Momin","year":"2019","unstructured":"Momin, N. et al. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci. Transl. Med. 11, eaaw2614 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1092_CR311","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgac244","volume":"1","author":"EA Lutz","year":"2022","unstructured":"Lutz, E. A. et al. Intratumoral nanobody\u2013IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice. PNAS Nexus 1, pgac244 (2022).","journal-title":"PNAS Nexus"},{"key":"1092_CR312","first-page":"3742","volume":"11","author":"E Mohiuddin","year":"2021","unstructured":"Mohiuddin, E. & Wakimoto, H. Extracellular matrix in glioblastoma: opportunities for emerging therapeutic approaches. Am. J. Cancer Res. 11, 3742 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"1092_CR313","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2024.102300","volume":"90","author":"E Ascic","year":"2025","unstructured":"Ascic, E. & Pereira, C.-F. Transcription factor\u2013mediated reprogramming to antigen-presenting cells. Curr. Opin. Genet. Dev. 90, 102300 (2025).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"1092_CR314","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/ni973","volume":"4","author":"R Dahl","year":"2003","unstructured":"Dahl, R. et al. Regulation of macrophage and neutrophil cell fates by the PU. 1: C\/EBP\u03b1 ratio and granulocyte colony-stimulating factor. Nat. Immunol. 4, 1029\u20131036 (2003).","journal-title":"Nat. Immunol."},{"key":"1092_CR315","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41590-021-00968-4","volume":"22","author":"TE Khoyratty","year":"2021","unstructured":"Khoyratty, T. E. et al. Distinct transcription factor networks control neutrophil-driven inflammation. Nat. Immunol. 22, 1093\u20131106 (2021).","journal-title":"Nat. Immunol."},{"key":"1092_CR316","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1389202911314020003","volume":"14","author":"S Haider","year":"2013","unstructured":"Haider, S. & Pal, R. Integrated analysis of transcriptomic and proteomic data. Curr. Genomics 14, 91\u2013110 (2013).","journal-title":"Curr. Genomics"},{"key":"1092_CR317","doi-asserted-by":"publisher","first-page":"M111.014910","DOI":"10.1074\/mcp.M111.014910","volume":"11","author":"M Imielinski","year":"2012","unstructured":"Imielinski, M. et al. Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse. Mol. Cell Proteomics 11, M111.014910 (2012).","journal-title":"Mol. Cell Proteomics"},{"key":"1092_CR318","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/blood-2013-05-500207","volume":"123","author":"AA Thompson","year":"2014","unstructured":"Thompson, A. A. et al. Hypoxia-inducible factor 2\u03b1 regulates key neutrophil functions in humans, mice, and zebrafish. Blood 123, 366\u2013376 (2014).","journal-title":"Blood"},{"key":"1092_CR319","doi-asserted-by":"publisher","first-page":"G53","DOI":"10.1152\/ajpgi.00182.2023","volume":"326","author":"R Singhal","year":"2024","unstructured":"Singhal, R. et al. Disruption of hypoxia-inducible factor-2\u03b1 in neutrophils decreases colitis-associated colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 326, G53\u2013G66 (2024).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1092_CR320","doi-asserted-by":"publisher","first-page":"175883592513178","DOI":"10.1177\/17588359251317846","volume":"17","author":"X Wu","year":"2025","unstructured":"Wu, X., Lazris, D., Wong, R. & Tykodi, S. S. Belzutifan for the treatment of renal cell carcinoma. Ther. Adv. Med. Oncol. 17, 17588359251317846 (2025).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1092_CR321","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.2217\/fon-2023-0283","volume":"19","author":"TK Choueiri","year":"2023","unstructured":"Choueiri, T. K. et al. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. Future Oncol. 19, 2631\u20132640 (2023).","journal-title":"Future Oncol."},{"key":"1092_CR322","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04736706 (2024)."},{"key":"1092_CR323","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67\u201376 (2017).","journal-title":"Lancet"},{"key":"1092_CR324","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma, P. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 18, 312\u2013322 (2017).","journal-title":"Lancet Oncol."},{"key":"1092_CR325","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard, C. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119\u20133125 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1092_CR326","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel, M. R. et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 19, 51\u201364 (2018).","journal-title":"Lancet Oncol."},{"key":"1092_CR327","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet, Y. et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann. Oncol. 30, 970\u2013976 (2019).","journal-title":"Ann. Oncol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01092-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01092-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01092-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:03:42Z","timestamp":1775649822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01092-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":327,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1092"],"URL":"https:\/\/doi.org\/10.1038\/s41585-025-01092-w","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"10 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}